Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.
[pleomorphic liposarcoma]
Soft
tissue
sarcomas
are
a
diverse
set
of
fatal
human
tumors
where
few
agents
have
demonstrable
clinical
efficacy
,
with
the
standard
therapeutic
combination
of
doxorubicin
and
ifosfamide
showing
only
a
25
%
to
30
%
response
rate
in
large
multi-institutional
trials
.
Although
liposarcomas
are
the
most
common
histologic
form
of
adult
soft
tissue
sarcomas
,
research
in
this
area
is
severely
hampered
by
the
lack
of
experimentally
tractable
in
vitro
model
systems
.
To
this
end
,
here
we
describe
a
novel
in
vitro
model
for
human
pleomorphic
liposarcoma
.
The
cell
line
(
LS
2
)
is
derived
from
a
pleomorphic
liposarcoma
that
uses
the
alternative
lengthening
of
telomeres
(
ALT
)
mechanism
of
telomere
maintenance
,
which
may
be
important
in
modulating
the
response
of
this
tumor
type
to
DNA-damaging
agents
.
We
present
detailed
baseline
molecular
and
genomic
data
,
including
genome-
wide
copy
number
and
transcriptome
profiles
,
for
this
model
compared
with
its
parental
tumor
and
a
panel
of
liposarcomas
covering
multiple
histologies
.
The
model
has
retained
essentially
all
of
the
detectable
alterations
in
copy
number
that
are
seen
in
the
parental
tumor
,
and
shows
molecular
karyotypic
and
expression
profiles
consistent
with
pleomorphic
liposarcomas
.
We
also
show
the
utility
of
this
model
,
together
with
two
additional
human
liposarcoma
cell
lines
,
to
investigate
the
relationship
between
topoisomerase
2
A
expression
and
the
sensitivity
of
ALT
-
positive
liposarcomas
to
doxorubicin
.
This
model
,
together
with
its
associated
baseline
data
,
provides
a
powerful
new
tool
to
develop
treatments
for
this
clinically
poorly
tractable
tumor
and
to
investigate
the
contribution
that
ALT
makes
to
modulating
sensitivity
to
doxorubicin
.
Diseases
Validation
Diseases presenting
"with the standard therapeutic combination of doxorubicin and ifosfamide showing only a 25%"
symptom
pleomorphic liposarcoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom